AU2018285710B2 - Methods and compositions for treating cancer - Google Patents

Methods and compositions for treating cancer Download PDF

Info

Publication number
AU2018285710B2
AU2018285710B2 AU2018285710A AU2018285710A AU2018285710B2 AU 2018285710 B2 AU2018285710 B2 AU 2018285710B2 AU 2018285710 A AU2018285710 A AU 2018285710A AU 2018285710 A AU2018285710 A AU 2018285710A AU 2018285710 B2 AU2018285710 B2 AU 2018285710B2
Authority
AU
Australia
Prior art keywords
polypeptide
val
elane
leu
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018285710A
Other languages
English (en)
Other versions
AU2018285710A1 (en
Inventor
Lev BECKER
Chang CUI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Chicago
Original Assignee
University of Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Chicago filed Critical University of Chicago
Publication of AU2018285710A1 publication Critical patent/AU2018285710A1/en
Application granted granted Critical
Publication of AU2018285710B2 publication Critical patent/AU2018285710B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/26—Endoribonucleases producing 5'-phosphomonoesters (3.1.26)
    • C12Y301/26003—Ribonuclease III (3.1.26.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21037—Leukocyte elastase (3.4.21.37), i.e. neutrophil-elastase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
AU2018285710A 2017-06-15 2018-06-15 Methods and compositions for treating cancer Active AU2018285710B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762520325P 2017-06-15 2017-06-15
US62/520,325 2017-06-15
US201762610711P 2017-12-27 2017-12-27
US62/610,711 2017-12-27
PCT/US2018/037800 WO2018232273A1 (en) 2017-06-15 2018-06-15 Methods and compositions for treating cancer

Publications (2)

Publication Number Publication Date
AU2018285710A1 AU2018285710A1 (en) 2020-01-23
AU2018285710B2 true AU2018285710B2 (en) 2025-02-13

Family

ID=64659547

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018285710A Active AU2018285710B2 (en) 2017-06-15 2018-06-15 Methods and compositions for treating cancer

Country Status (9)

Country Link
US (1) US12564623B2 (https=)
EP (2) EP4292606B1 (https=)
JP (3) JP7189160B2 (https=)
CN (1) CN111032075A (https=)
AU (1) AU2018285710B2 (https=)
CA (1) CA3066738A1 (https=)
DK (1) DK3638293T5 (https=)
ES (2) ES2962985T3 (https=)
WO (1) WO2018232273A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019403393B2 (en) * 2018-12-20 2026-04-16 The University Of Chicago Methods and compositions related to therapeutic peptides for cancer therapy
CA3184037A1 (en) * 2020-08-18 2022-02-24 Onchilles Pharma, Inc. Modified serine protease proproteins
EP4199947A4 (en) * 2020-08-18 2024-10-16 Onchilles Pharma, Inc. Modified porcine pancreatic elastase proteins
CN112812150A (zh) * 2021-01-29 2021-05-18 深圳海创生物科技有限公司 一种活性环肽、活性环肽组合物及其在制备具有抗氧化或抗炎作用的产品中的应用
CN113736742B (zh) * 2021-09-08 2023-07-21 河南省医药科学研究院 Prtn3基因作为肿瘤免疫治疗中激活细胞毒性免疫细胞靶点的应用
CN115040642B (zh) * 2022-06-30 2025-03-28 德博尔(成都)生物科技有限公司 一种胰弹性蛋白酶的新用途
CN118443941A (zh) * 2024-04-29 2024-08-06 山东大学齐鲁医院 中性粒细胞作为诊疗膀胱癌的靶标的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
UA27035C2 (uk) 1990-08-03 2000-02-28 Вертекс Фармас'Ютікалс Інкорпорейтід Кристал білка, зшитого багатофуhкціоhальhим зшивальним агеhтом (варіаhти), пристрій, що містить кристал білка та спосіб отримаhhя аспартаму
US5698518A (en) * 1994-03-30 1997-12-16 Oklahoma Medical Research Foundation Method for regulating inflammation and tumor growth with calmodulin, calmodulin analogues or calmodulin antagonists
AU2003231981A1 (en) * 2002-03-29 2003-10-13 Incyte Corporation Protein modification and maintenance molecules
CA2500405A1 (en) 2002-09-30 2004-04-15 Oncotherapy Science, Inc. Genes and polypeptides relating to human myeloid leukemia
JP4408615B2 (ja) 2002-10-07 2010-02-03 独立行政法人科学技術振興機構 好酸球カチオン性タンパク質を含有する組成物
US8068990B2 (en) 2003-03-25 2011-11-29 Hologic, Inc. Diagnosis of intra-uterine infection by proteomic analysis of cervical-vaginal fluids
EP1639090A4 (en) * 2003-06-09 2008-04-16 Univ Michigan COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
EP1649289B1 (en) 2003-07-21 2008-10-22 Roche Diagnostics GmbH Use of proteins proteinase 3 (prn3) and leukocyte elastase inhibitor (ileu) as a marker for colorectal cancer
US7432419B2 (en) * 2004-05-14 2008-10-07 Los Alamos National Security, Llc Compositions and methods for the treatment of Pierce's disease
US20060008891A1 (en) 2004-06-23 2006-01-12 The Government Of Usa As Repersented By The Secretary, Department Of Health And Human Services Cathepsin G-related peptides as modulators of formylpeptide receptors (FPR)
US20060045881A1 (en) 2004-08-26 2006-03-02 Board Of Regents, The University Of Texas System Anti-cancer vaccines
US8501449B2 (en) * 2007-12-04 2013-08-06 Proteon Therapeutics, Inc. Recombinant elastase proteins and methods of manufacturing and use thereof
WO2010009368A2 (en) * 2008-07-18 2010-01-21 Oragenics, Inc. Compositions for the detection and treatment of colorectal cancer
GB201121070D0 (en) 2011-12-07 2012-01-18 Isis Innovation composition for delivery of biotherapeutics
WO2016125330A1 (ja) 2015-02-02 2016-08-11 原　英彰 網膜再生促進薬

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AI-SHENG HO ET AL: "Neutrophil elastase as a diagnostic marker and therapeutic target in colorectal cancers", ONCOTARGET, 30 January 2014, pages 473 - 480, www.ncbi.nlm.nih.gov/pmc/articles/PMC3964222/pdf/oncotarget-05-473.pdf *
PRISCILA OLIVEIRA DE LIMA ET AL: "Effect of eosinophil cationic protein on human oral squamous carcinoma cell viability", MOLECULAR AND CLINICAL ONCOLOGY, vol. 3, no. 2, 16 December 2014 (2014-12-16), GR, pages 353 - 356. *

Also Published As

Publication number Publication date
JP7189160B2 (ja) 2022-12-13
EP4292606B1 (en) 2025-11-12
EP4292606A3 (en) 2024-02-21
DK3638293T5 (da) 2024-08-26
EP4292606A2 (en) 2023-12-20
EP3638293A4 (en) 2021-03-10
US20210299234A1 (en) 2021-09-30
CN111032075A (zh) 2020-04-17
WO2018232273A1 (en) 2018-12-20
JP2020524141A (ja) 2020-08-13
AU2018285710A1 (en) 2020-01-23
EP3638293A1 (en) 2020-04-22
JP2023022242A (ja) 2023-02-14
ES3055526T3 (en) 2026-02-12
EP3638293B1 (en) 2023-10-04
DK3638293T3 (da) 2023-11-06
ES2962985T3 (es) 2024-03-22
CA3066738A1 (en) 2018-12-20
US12564623B2 (en) 2026-03-03
JP7529754B2 (ja) 2024-08-06
JP2024150679A (ja) 2024-10-23

Similar Documents

Publication Publication Date Title
AU2018285710B2 (en) Methods and compositions for treating cancer
US20230201305A9 (en) Immune checkpoint inhibitor combinations
EP2234642B1 (en) Method of increasing immunological effect
JP2026021440A (ja) がん治療のための治療用ペプチドに関する方法および組成物
WO2019213686A1 (en) Therapeutic compositions and uses therefor
EP2833900B1 (en) Extracellular matrix metalloproteinase inducer (emmprin) peptides and binding antibodies
HK40102823A (en) Compositions for treating cancer
HK40102823B (en) Compositions for treating cancer
HK40029045B (en) Compositions for treating cancer
HK40029045A (en) Compositions for treating cancer
US12611443B2 (en) Methods and compositions related to therapeutic peptides for cancer therapy
Orsolic Possible molecular targets of bee venom in the treatment of cancer: application and perspectives
US20150353912A1 (en) Methods for treating and preventing radiation injury using activated protein c polypeptides
WO2017042318A1 (en) Chemerin polypeptide for the treatment of cancer-induced cachexia
US20150258194A1 (en) Modulating transendothelial migration and recruitment of granulocytes by modulating c-met pathway
HK1150303A (en) Method of increasing immunological effect
HK1150303B (en) Method of increasing immunological effect

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)